BioSpace News Archive

Submitted Pre-IND briefing package outlining proposed clinical development program for Ii-Key-SARS-CoV-2 prophylactic peptide vaccine against the coronavirus pandemic Final protocol submitted with package to conduct a Phase I/II human clinical trial

Sarnova announced today that it will acquire and simultaneously combine Digitech and the R1 RCM Inc. (“R1") EMS business (formerly ADPI/Intermedix), in partnership with Pamlico Capital and Digitech Founder and CEO Mark S

PHASE Scientific, a fast-growing biotechnology company, announces today it has received the Conformité Européene (CE) Mark approval for its PHASIFY ™ VIRAL RNA Extraction Kit. The CE marking confirms that PHASIFY ™ V

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its stockholders, employees and others,

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that

Duality Technologies partners with Harvard Medical School and Two Six Labs to accelerate privacy-preserving, collaborative machine learning protected through Homomorphic Encryption. This capability supports research into COVID-19 susceptibility while keeping patient data private and secure. [20-July-2020] NEWARK, N.J. , July 20, 2020 /PRNewswire/ -- Duality Techno

- Abivertinib is a novel Tyrosine Kinase Inhibitor with dual selective targeting of mutant forms of EGFR and BTK that has completed a registration trial (lung cancer) and been administered to over 600 patients worldwide. - The compound demonstrated in-vitro the ability to simultaneously lower multiple critical inflammatory cytokines associated with cytokine storm and poor prognosis in COVID-19 patients. - It is to be tested next in a Phase 2 trial in moderate to severe COVID-

The Leukemia & Lymphoma Society (LLS) announced today National Board Officer appointments and four new members to its National Board of Directors, who will work alongside LLS leadership to ensure that the organization continues to deliver its cancer curing mission and impact for patients, despite the challenges caused by the COVID-19 pandemic.

Growth Among Regional and National Health Plans Driven by ROI and Member Net Promoter Score of 92

Modern Vascular, a pioneering medical group dedicated to preventing amputation through the treatment of peripheral artery disease in the lower leg, announced the expansion of its national footprint with the opening of its newest office in Southaven, MS.